Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab.

Literature DB >> 26140234

Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab.

Xiao Ni¹, Timothy Langridge¹, Madeleine Duvic¹.

Abstract

The CC chemokine receptor 4 (CCR4) is highly expressed on type 2 helper T cells and regulatory T (Treg) cells. Mogamulizumab, an anti-CCR4 antibody, reduces the numbers of CCR4+ malignant T cells and CCR4+ Treg cells in cutaneous T-cell lymphoma. Depleting Treg cells by targeting CCR4 has great potential in cancer immunotherapies.

Entities: Chemical Disease Gene

Keywords: Sézary syndrome; chemokine receptor; cutaneous T-cell lymphoma; mogamulizumab; monoclonal antibody; mycosis fungoides; regulatory T cells; targeted therapy

Year: 2015 PMID： 26140234 PMCID： PMC4485778 DOI： 10.1080/2162402X.2015.1011524

Source DB: PubMed Journal: Oncoimmunology ISSN： 2162-4011 Impact factor: 8.110

9 in total

Review 1. [Development of an anti-CCR4 antibody, mogamulizumab, the first approved antibody made by POTELLIGENT(®) technology].

Authors: Toshihiko Ishii
Journal: Nihon Yakurigaku Zasshi Date: 2013-10

2. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.

Authors: Daisuke Sugiyama; Hiroyoshi Nishikawa; Yuka Maeda; Megumi Nishioka; Atsushi Tanemura; Ichiro Katayama; Sachiko Ezoe; Yuzuru Kanakura; Eiichi Sato; Yasuo Fukumori; Julia Karbach; Elke Jäger; Shimon Sakaguchi
Journal: Proc Natl Acad Sci U S A Date: 2013-10-14 Impact factor: 11.205

3. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.

Authors: Madeleine Duvic; Lauren C Pinter-Brown; Francine M Foss; Lubomir Sokol; Jeffrey L Jorgensen; Pramoda Challagundla; Karen M Dwyer; Xiaoping Zhang; Michael R Kurman; Rocco Ballerini; Li Liu; Youn H Kim
Journal: Blood Date: 2015-01-20 Impact factor: 22.113

Review 4. Regulatory T cell as a target for cancer therapy.

Authors: Lucas Cunha Dias de Rezende; Ian Victor Silva; Letícia Batista Azevedo Rangel; Marco Cesar Cunegundes Guimarães
Journal: Arch Immunol Ther Exp (Warsz) Date: 2010-04-07 Impact factor: 4.291

5. In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study.

Authors: Youn H Kim; Dita Gratzinger; Cameron Harrison; Joshua D Brody; Debra K Czerwinski; Weiyun Z Ai; Anjali Morales; Farah Abdulla; Leon Xing; Daniel Navi; Robert J Tibshirani; Ranjana H Advani; Bharathi Lingala; Sumit Shah; Richard T Hoppe; Ronald Levy
Journal: Blood Date: 2011-11-01 Impact factor: 22.113

6. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.

Authors: Xiao Ni; Jeffrey L Jorgensen; Meghali Goswami; Pramoda Challagundla; William K Decker; Youn H Kim; Madeleine A Duvic
Journal: Clin Cancer Res Date: 2014-11-05 Impact factor: 12.531

7. Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma.

Authors: D Jones; C O'Hara; M D Kraus; A R Perez-Atayde; A Shahsafaei; L Wu; D M Dorfman
Journal: Blood Date: 2000-07-15 Impact factor: 22.113

8. Induction of T-cell responses against cutaneous T-cell lymphomas ex vivo by autologous dendritic cells transfected with amplified tumor mRNA.

Authors: Xiao Ni; Heather M Richmond; Xingsheng M Liao; William K Decker; Lisa H Shiue; Elizabeth J Shpall; Madeleine Duvic
Journal: J Invest Dermatol Date: 2008-05-15 Impact factor: 8.551

Review 9. The targeting of immunosuppressive mechanisms in hematological malignancies.

Authors: M H Andersen
Journal: Leukemia Date: 2014-03-18 Impact factor: 11.528

9 in total

10 in total

Review 1. Immunosuppressive cells in tumor immune escape and metastasis.

Authors: Yang Liu; Xuetao Cao
Journal: J Mol Med (Berl) Date: 2015-12-22 Impact factor: 4.599

Review 2. Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.

Authors: Ryan A Wilcox
Journal: Am J Hematol Date: 2015-11-26 Impact factor: 10.047

Review 3. The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Current and future approaches.

Authors: David M Weiner; Joseph S Durgin; Maria Wysocka; Alain H Rook
Journal: J Am Acad Dermatol Date: 2020-12-22 Impact factor: 11.527

Review 4. Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines.

Authors: Michael R Pranzatelli
Journal: Front Immunol Date: 2018-04-04 Impact factor: 7.561

Review 5. The role of regulatory T cells and genes involved in their differentiation in pathogenesis of selected inflammatory and neoplastic skin diseases. Part II: The Treg role in skin diseases pathogenesis.

Authors: Bogusław Nedoszytko; Magdalena Lange; Małgorzata Sokołowska-Wojdyło; Joanna Renke; Piotr Trzonkowski; Michał Sobjanek; Aneta Szczerkowska-Dobosz; Marek Niedoszytko; Aleksandra Górska; Jan Romantowski; Justyna Czarny; Jarosław Skokowski; Leszek Kalinowski; Roman Nowicki
Journal: Postepy Dermatol Alergol Date: 2017-10-31 Impact factor: 1.837

10. Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study.

Authors: Benjamin A Derman; Yuanyuan Zha; Todd M Zimmerman; Rebecca Malloy; Andrzej Jakubowiak; Michael R Bishop; Justin Kline
Journal: J Immunother Cancer Date: 2020-01 Impact factor: 13.751